TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Impaired jump performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased muscle soreness
Endpoint domain: Adverse events/effects
Primary endpoint: Increased CK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional patient free of tumour recurrence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: TGF-beta expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-11 and IL-17 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Types I and III collagens expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum BDNF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength of lower‐extremity extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reappearance of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental experience of environmental stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in creatinine concentrations postcontrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: state-anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective tension levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tranquility levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size determined by creatine kinase‐MB area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular size or function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: quit intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MST (Mean Skin Temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBT (Mean Body Temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Successful intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of TEAEs leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of systolic blood pressure increase greater than 15 percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to stroke unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa daily dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV RNA < 400 copies/mL at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEF25‐75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Caregivers' perception of children's QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total consumption of sufentanil (μg) in 24 hours after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting and movement VAS scores at 2, 4, 8, and 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of nausea and vomiting within 24 hours after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Readmission rates for targeted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission rates for nontargeted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHEAS concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Androstenedione concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hcy (Homocysteine) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Outpatient visit for asthma
Endpoint domain: Mortality/survival
Primary endpoint: intention to seek help with insurance navigation and care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: beliefs concerning preventive care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for the novel brush
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: low-density lipoprotein (LDL) cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in NPDS‐I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma and rhinitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated caloric expenditure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of postoperative febrile morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Pain suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solid fusion rate at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Effective Rate (TER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pruritus Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and quantity of HHV-8 replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of narcotic analgesia required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platinum levels in abdominal lymphatic nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of retroperitoneal lymphatic metastasis after resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Chest excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma levels of calcitonin gene‐related peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of PACAP38
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-5L VAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SWN-S physical functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: percentage of stent obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of inflammatory mediators (IL-6, CRP, leukocytes, fibrinogen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Management change prompted by microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta VE45
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: body weight z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analogue scale (VAS) score for initial pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of itching
Endpoint domain: Adverse events/effects
Primary endpoint: social involvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: employment status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: health behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum levels of interleukin 6 (IL‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble E‐selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maintenance of non-anaemic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: throat soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in dietary recommendations
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: improvement in work index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvement in sport index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: appendicular skeletal muscle mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lean body mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improvement of lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DAR‐901 antigen‐specific polyfunctional or bifunctional T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Temperature testing and vibration perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary NAG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endometrial MMP‐9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial TIMP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nodular disease as a predictor of ADR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Vesikari scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: alcohol use quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading Task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shallower residual pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of periodontal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time for appearance of newly blister and scabbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time for relieving pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHN incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: CBF velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(0, infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time between referral and response
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of BRONJ
Endpoint domain: Adverse events/effects
Primary endpoint: Blood flow change in response to adrenaline infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bodily pain at 1 month postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bodily pain at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: social functioning at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum HBV DNA < or = 4700 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroconversion to anti‐HBe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky performance status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mobility disability (MMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net fluid loss per 40 mg furosemide equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine output produced per 40 mg furosemide equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweating interference with daily activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth surface loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular health problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent-reported trauma level of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child distress levels during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total procedural time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sinus rhythm maintenance after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular ejection fraction recovery after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: context-sensitive half-time for remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: context-sensitive half-time for alfentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal elimination half-life for remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal elimination half-life for alfentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perfusion flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Productivity loss
Endpoint domain: Life impact
Endpoint subdomain: Economic burden
Primary endpoint: Annual decline in ADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Annual decline in IADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reductions in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reductions in total cholesterol and LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reductions in BMI, weight and waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gingival outcome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiomegaly in chest X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of at least 1 colorectal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of at least 1 advanced lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: prevalence of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Response (DoR)
Endpoint domain: Mortality/survival
Primary endpoint: mean bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to PMN engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staple line dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Diastolic Blood Pressure (DBP) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Peripheral Resistance (TPR) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of treated diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Insulin resistance (homeostasis model assessment of insulin resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma lathosterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevalence and intensity of S. mansoni infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduced side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Caries detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or neurologic impairment
Endpoint domain: Mortality/survival
Primary endpoint: slowing of cognitive speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG activation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increment of (C)isoBrain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal inspiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obesity risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fecal sIgA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-poliovirus-specific IgA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-rotavirus-specific IgA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: severity scores of stretch marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean length of stretch marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean width of stretch marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of platelet-transfusion dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rate of death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of sustained ventricular arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in functional status (NYHA class)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean duration of surgical wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean duration of hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Shear Bond Strength (SBS) of composite resin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation in the DLPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: End-diastolic volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-systolic volume (ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of patients with adherence deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) domains impacted by ovarian cancer
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in serum interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total intra-abdominal fat volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: isokinetic trunk flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isokinetic trunk extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes